The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor modulator https://bookmarkingdelta.com/story21601104/retatrutide-and-nmn-a-triple-threat-approach-to-physiological-health